ArticleMicromachines2026
From Simulation to Application: Droplet-Based Microfluidics for Thermal Targeting of Cancer Cells.
Article in Micromachines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This paper presents the development, fabrication, and characterization of a droplet-based microfluidic platform designed for precise local thermal treatment of cancer cells, with prospective chemical targeting as a future application. The workflow begins with a finite element model (FEM) using COMSOL Multiphysics 6.0 to characterize coupled hydrodynamic and thermal behavior, specifically analyzing temperature distributions across single-phase and three-phase regimes. Following the simulation, work has progressed to the fabrication of a microfluidic device and the characterization of its platinum heat source and temperature detector to ensure precise thermal control. To replicate realistic biochemical conditions, experiments have employed a three-phase configuration of oil, water, and fluorescent BSA solution. In the final stage, DX5-GFP MES-SA cancer cells have replaced the BSA solution to complete the measurements. To ensure reagent homogenization and consistent cellular exposure, a serpentine channel design was utilized to induce Dean vortices, which significantly enhanced internal mixing within the droplets. Fluorescence-loss experiments demonstrated that localized heating above ~60 °C induces irreversible thermal damage in both model proteins (fluorescent BSA) and cancer cells, establishing a proof-of-concept basis for precise thermal regulation at the single-droplet level. By deactivating specific thermo-sensitive proteins responsible for drug resistance, this integrated approach to thermal and hydrodynamic optimization enhances the efficacy of chemical stimuli and provides a robust platform for investigating the modulation of cellular defense mechanisms in future biotechnological applications. The platform holds significant potential for advancing precision oncology by enabling systematic, single-cell-level investigation of heat-shock-mediated drug sensitization, with long-term implications for overcoming multidrug resistance in aggressive cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.